This week, I’m stepping away from my usual updates on the Social Determinants of Health (SDoH) to share a deeply personal experience. I hope that by bringing this issue to light, we can foster collective growth and learning.
Although I typically keep my personal medical journey private, recent events have compelled me to speak out.
In January 2019, I was diagnosed with Stage 3 Hodgkin lymphoma. Since then, I’ve undergone various treatments, including a stem-cell transplant. Fortunately, for the past two years, a drug called Keytruda has helped keep my cancer at bay, with minimal side effects and significant remission. However, about a month ago, I was blindsided by a denial from my insurance company. The denial came because I had reached the two-year mark on Keytruda, which is the period the insurance company deemed sufficient.
This decision was not only surprising but also disheartening. Despite significant help in filing an appeal from Dr. Kendall Smith at PayerWatch, and my husband, Ryan O’Hara, spending over 18 hours on calls with CareFirst BlueCross BlueShield and CVS Caremark, and presenting evidence from recent studies, my efforts to overturn this denial have been unsuccessful. The insurance company has opted to rely on a four-year-old clinical study rather than the most recent research, which demonstrates that Keytruda continues to be effective, with a 22-percent full remission rate as of Sept. 7, 2023.
The denial of lifesaving treatment by these for-profit entities is a stark reminder of the challenges many face in accessing necessary healthcare. This is not merely about my personal treatment, but a broader issue affecting countless individuals. My oncologist, a respected expert at Mayo Clinic, has prescribed this treatment based on its proven effectiveness and cost-efficiency. Yet, it appears that my insurance has prioritized cost savings over long-term healthcare effectiveness.
As someone who obviously works in the healthcare field, I am familiar with the complexities of navigating this system. I am actively working on alternative plans, but this situation demonstrates a harsh reality: many people lack the resources or knowledge to advocate for themselves effectively. This denial of care, despite my access to support and expertise, raises serious questions about how patients without such resources cope with similar challenges.
The frustration of dealing with an insurance company that seems more concerned with cutting costs than saving lives is compounded by the personal stakes involved. This is not just about me; it’s about the broader issue of insurance companies dictating the terms of care, often while overriding the recommendations of dedicated medical professionals.
In sharing my story, I hope to shed light on this critical issue and encourage a dialogue about the need for systemic change. No one should have to fight for access to lifesaving treatment, and no healthcare decision should be driven by profit rather than patient welfare. The goal should always be to ensure that every patient receives the care they need.
References:
Armand P, Zinzani PL, Lee HJ, Johnson NA, Brice P, Radford J, Ribrag V, Molin D, Vassilakopoulos TP, Tomita A, von Tresckow B, Shipp MA, Herrera AF, Lin J, Kim E, Chakraborty S, Marinello P, Moskowitz CH. Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed/refractory classical Hodgkin lymphoma. Blood. 2023 Sep 7;142(10):878-886. doi: 10.1182/blood.2022019386. PMID: 37319435; PMCID: PMC10624931
EDITOR’S NOTE:
The opinions expressed in this article are solely those of the author and do not necessarily represent the views or opinions of MedLearn Media. We provide a platform for diverse perspectives, but the content and opinions expressed herein are the author’s own. MedLearn Media does not endorse or guarantee the accuracy of the information presented. Readers are encouraged to critically evaluate the content and conduct their own research. Any actions taken based on this article are at the reader’s own discretion.
When I was a resident, no one ever said to me, “Pay attention. One day this will matter when you are explaining medical necessity to
Beginning in 2026, the Centers for Medicare & Medicaid Services (CMS) will begin phasing out the Inpatient-Only (IPO) List by removing predominantly musculoskeletal and complex
Please log in to your account to comment on this article.
Gain clarity and confidence in OB‑GYN coding with this expert‑led webcast featuring Stacey Shillito, CDIP, CPMA, CCS, CCS‑P, CPEDC, COPC. You’ll learn how to apply global maternity package rules accurately, select the right CPT codes for procedures and visits, and identify documentation gaps that lead to denials. With practical guidance and real examples, this session helps you strengthen compliance, reduce audit risk, and ensure accurate reimbursement for women’s health services.
Uncover essential coding insights with nationally recognized coding authority Kay Piper, RHIA, CDIP, CCS. Through ICD10monitor’s interactive, on‑demand webcast series, Kay walks you through the AHA’s 2026 ICD‑10‑CM/PCS Quarterly Coding Clinics, translating each update into practical, easy‑to‑apply guidance designed to sharpen precision, ensure compliance, and strengthen day‑to‑day decision‑making. Available shortly after each official release.
Uncover critical guidance on the ICD-10-CM/PCS code updates. Kay Piper reviews and explains ICD-10-CM/PCS coding guidelines in the AHA’s fourth quarter 2026 ICD-10-CM/PCS Coding Clinic in an easy to access on-demand webcast.
Uncover critical guidance on the ICD-10-CM/PCS code updates. Kay Piper reviews and explains ICD-10-CM/PCS coding guidelines in the AHA’s third quarter 2026 ICD-10-CM/PCS Coding Clinic in an easy to access on-demand webcast.
Federal auditors are intensifying their focus on inpatient psychiatric facilities, using advanced data analytics to spotlight outliers and pursue high‑dollar repayments. In this high‑impact webcast, Michael Calahan, PA, MBA, Compliance Officer and V.P., Hospital & Physician Compliance, breaks down what regulators are really targeting in IPF-PPS admissions, documentation, treatment and discharge planning. Attendees will learn practical steps to tighten processes, avoid common audit triggers and protect reimbursement and reduce the risk of multimillion-dollar repayment demands.
In this timely session, Stacey Shillito, CDIP, CPMA, CCS, CCS-P, CPEDC, COPC, breaks down the complexities of Medical Decision Making (MDM) documentation so providers can confidently capture the true complexity of their care. Attendees will learn practical, efficient strategies to ensure documentation aligns with current E/M guidelines, supports accurate coding, and reduces audit risk, all without adding to charting time.
Join Ronald Hirsch, MD, FACP, CHCQM for The PEPPER Returns – Risk and Opportunity at Your Fingertips, a practical webcast that demystifies the PEPPER and shows you how to turn complex claims data into actionable insights. Dr. Hirsch will explain how to interpret key measures, identify compliance risks, uncover missed revenue opportunities, and understand new updates in the PEPPER, all to help your organization stay ahead of audits and use this powerful data proactively.
Stay ahead of the 2026-2027 audit surge with “Top 10 Audit Targets for 2026-2027 for Hospitals & Physicians: Protect Your Revenue,” a high-impact webcast led by Michael Calahan, PA, MBA. This concise session gives hospitals and physicians clear insight into the most likely federal audit targets, such as E/M services, split/shared and critical care, observation and admissions, device credits, and Two-Midnight Rule changes, and shows how to tighten documentation, coding, and internal processes to reduce denials, recoupments, and penalties. Attendees walk away with practical best practices to protect revenue, strengthen compliance, and better prepare their teams for inevitable audits.
Prepare for the 2025 CMS IPPS Final Rule with ICD10monitor’s IPPSPalooza! Click HERE to learn more
Get 15% OFF on all educational webcasts at ICD10monitor with code JULYFOURTH24 until July 4, 2024—start learning today!
BLOOM INTO SAVINGS! Get 25% OFF during our spring sale through March 27. Use code SPRING26 at checkout to claim this offer.
CYBER WEEK IS HERE! Don’t miss your chance to get 20% off now until Dec. 1 with code CYBER25
CYBER WEEK IS HERE! Don’t miss your chance to get 20% off now until Dec. 2 with code CYBER24
